Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma

Unconjugated, toxin-conjugated or radiolabeled antibodies (Ab) recognizing tumor-associated antigens have proven beneficial for solid and hematolymphoid neoplasms. A suitable antigen for targeted therapy could be Prostate Stem Cell Antigen (PSCA), a cell surface-antigen expressed at low levels in normal prostate and over expressed in prostate, pancreatic and bladder carcinoma. Anti PSCA mAb was obtained by hybridoma technology and a recombinant version in single chain format (scFv) was generated by cloning the variable heavy (VH) and light chain (VL) sequences in the expression vector pHEN-2. mAb and scFv ability to recognize native PSCA was assessed by flow cytometry on SW780 (PSCA+) cells. The mAb demonstrated a good specificity and affinity, whereas the scFv showed a lower staining compared to whole mAb. The affinity/avidity of scFv was partially recovered making it divalent by cross-linking myc Tag by pre-incubation with anti myc-Ab. mAb was also able to recognize the glycosylated PSCA on prostate and pancreatic neoplastic tissue lysates by Western Blot. The antibody internalization assay demonstrated that the Ab-PSCA complex was internalized. This property was exploited for intracellular delivering of cytotoxic agents. The sequence coding for the Pseudomonas aeruginosa exotoxin A mutant PE40 was cloned at the 3′-end of the scFv yielding an anti-PSCA recombinant immunotoxin. Analysis of cytotoxic activity and specificity of scFv-PE40 are on-goin